172 related articles for article (PubMed ID: 37012059)
1. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE.
Askanase AD; Tang W; Zuraw Q; Gordon R; Brotherton B; Merrill JT
Lupus Sci Med; 2023 Apr; 10(1):. PubMed ID: 37012059
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort.
Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Zeña-Huancas P; Elera-Fitzcarrald C; Garcia-Hirsh S; Gil L; Pastor-Asurza CA; Rodriguez-Bellido Z; Merrill J; Askanase AD; Alarcon G; Perich-Campos RA
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33046557
[TBL] [Abstract][Full Text] [Related]
3. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
4. The Lupus Foundation of America-Rapid Evaluation of Activity in Lupus Clinician-Reported Outcome Predicts Damage in Patients With Systemic Lupus Erythematosus. Data From the Almenara Lupus Cohort.
Ugarte-Gil MF; Gamboa-Cárdenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Elera-Fitzcarrald C; Pastor-Asurza C; Rodriguez-Bellido Z; Perich-Campos R; Alarcón GS
J Clin Rheumatol; 2024 Jun; ():. PubMed ID: 38880959
[TBL] [Abstract][Full Text] [Related]
5. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures.
Thanou A; James JA; Arriens C; Aberle T; Chakravarty E; Rawdon J; Stavrakis S; Merrill JT; Askanase A
Lupus Sci Med; 2019; 6(1):e000365. PubMed ID: 31921432
[TBL] [Abstract][Full Text] [Related]
6. The Spectrum of Health Domains Important to Lupus Patients Early Development of a Disease Activity Patient Reported Outcome.
Askanase AD; Nguyen S; Neville K; Danias G; Hanrahan LM; Merrill JT
Bull Hosp Jt Dis (2013); 2019 Mar; 77(2):92-98. PubMed ID: 31128578
[TBL] [Abstract][Full Text] [Related]
7. Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity.
Askanase AD; Daly RP; Okado M; Neville K; Pong A; Hanrahan LM; Merrill JT
Health Qual Life Outcomes; 2019 Jun; 17(1):99. PubMed ID: 31174541
[TBL] [Abstract][Full Text] [Related]
8. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments.
Askanase A; Li X; Pong A; Shum K; Kamp S; Carthen F; Aberle T; Hanrahan L; Daly P; Giles J; Merrill JT
Lupus Sci Med; 2015; 2(1):e000075. PubMed ID: 25861457
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
van Vollenhoven RF; Hahn BH; Tsokos GC; Lipsky P; Fei K; Gordon RM; Gregan I; Lo KH; Chevrier M; Rose S
Arthritis Rheumatol; 2020 May; 72(5):761-768. PubMed ID: 31769212
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians.
Askanase AD; Nguyen SC; Costenbader K; Lim SS; Kamen D; Aranow C; Grossman J; Kapoor TM; Baker-Frost D; Aberle T; Thanou-Stavraki A; Hanrahan LM; Kim M; Merrill JT
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1058-1063. PubMed ID: 28992399
[TBL] [Abstract][Full Text] [Related]
11. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial.
Jolly M; Annapureddy N; Arnaud L; Devilliers H
Lupus; 2019 Dec; 28(14):1628-1639. PubMed ID: 31674267
[TBL] [Abstract][Full Text] [Related]
12. Impaired health status and the effect of pain and fatigue on functioning in clinical trial patients with systemic lupus erythematosus.
Petri M; Kawata AK; Fernandes AW; Gajria K; Greth W; Hareendran A; Ethgen D
J Rheumatol; 2013 Nov; 40(11):1865-74. PubMed ID: 24085548
[TBL] [Abstract][Full Text] [Related]
13. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
Furie R; Morand EF; Bruce IN; Isenberg D; van Vollenhoven R; Abreu G; Pineda L; Tummala R
Arthritis Rheumatol; 2021 Nov; 73(11):2059-2068. PubMed ID: 33913260
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Lipsky P; Gordon RM; Fei K; Lo KH; Chevrier M; Rose S; Berry P; Yao Z; Karyekar CS; Zuraw Q
J Rheumatol; 2022 Apr; 49(4):380-387. PubMed ID: 34853089
[TBL] [Abstract][Full Text] [Related]
15. Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76).
Rendas-Baum R; Baranwal N; Joshi AV; Park J; Kosinski M
J Patient Rep Outcomes; 2021 Apr; 5(1):33. PubMed ID: 33830377
[TBL] [Abstract][Full Text] [Related]
16. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
Petri MA; Martin RS; Scheinberg MA; Furie RA
Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505
[TBL] [Abstract][Full Text] [Related]
17. The use of patient-reported outcome measures to classify type 1 and 2 systemic lupus erythematosus activity.
Eudy AM; Reeve BB; Coles T; Lin L; Rogers JL; Pisetsky DS; Criscione-Schreiber LG; Doss J; Sadun R; Sun K; Clowse ME
Lupus; 2022 May; 31(6):697-705. PubMed ID: 35343853
[TBL] [Abstract][Full Text] [Related]
18. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab.
Strand V; O'Quinn S; Furie RA; Morand EF; Kalunian KC; Schwetje EG; Abreu G; Tummala R
Lancet Rheumatol; 2022 Mar; 4(3):e198-e207. PubMed ID: 38288936
[TBL] [Abstract][Full Text] [Related]
19. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
[TBL] [Abstract][Full Text] [Related]
20. Novel evidence-based systemic lupus erythematosus responder index.
Furie RA; Petri MA; Wallace DJ; Ginzler EM; Merrill JT; Stohl W; Chatham WW; Strand V; Weinstein A; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1143-51. PubMed ID: 19714615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
